Author: MedCity News

The News Aggregator will pull the latest articles and news from around the internet to present them in one place for you to easily keep up to date on all things related to Medical Informatics. MedCity News is the leading online news source for the business of innovation in healthcare. Medcity News offers insights into what’s next and what matters with a mix of breaking news and analysis on startups, and established industry leaders, personalities, policies and the most important deals.
Cell Therapy Biotech Talaris Ends Two Kidney Transplant Trials, Restructures

Cell Therapy Biotech Talaris Ends Two Kidney Transplant Trials, Restructures

MedCity News

Talaris Therapeutics aimed to transform solid organ transplants with a cell therapy that replaces anti-rejection drugs patients need for the rest of their lives. But after clinical trial setbacks, the biotech has decided to end two kidney transplant studies. Although a separate test of its experimental therapy is continuing in a rare autoimmune condition, Talaris has commenced a restructuring plan that it said could culminate in a merger or sale of the company.
The restructuring announced Thursday will lead to the layoff of about one-third of Talaris’s staff. As of the end of the third quarter of 2022, the Louisville, Kentucky-based biotech…

Continue Reading
3 Conditions that Must be Met to Make Interoperability a Reality

3 Conditions that Must be Met to Make Interoperability a Reality

MedCity News

The term “interoperability” holds different meanings for different people. While we all would agree that the primary goal of interoperability is to make sharing data easier in order to improve outcomes and lower costs, there are varying perceptions about what that looks like. FHIR has been great at giving us a common set of protocols and standards to work from, but how we connect and how data actually gets shared are still open challenges.
In a truly interoperable healthcare ecosystem, I strongly believe data wouldn’t need to be requested, aggregated, and validated each time it’s needed. And it wouldn’t be limited to specific…

Continue Reading
Digital as the Differentiator for Biopharma and Medtech

Digital as the Differentiator for Biopharma and Medtech

MedCity News

With the Inflation Reduction Act now on the books, the U.S. Centers for Medicare & Medicaid Services (CMS) will begin negotiating drug prices with the pharmaceutical industry. That, combined with other headwinds such as increased competition from me-too drugs, and ever-present pricing pressure from payers, means that pharma players now more than ever need a new and powerful tool to differentiate their products. We believe the next decade of transformation is digital.
Learning from the auto industry Almost every industry has had to confront a fundamental existential question: What is our product? Consider the automotive industry, which once was largely about hardware…

Continue Reading
Elation Health Buys Medical Billing Company to Create All-in-One Tech Platform for Primary Care Providers

Elation Health Buys Medical Billing Company to Create All-in-One Tech Platform for Primary Care Providers

MedCity News

Elation Health — a San Francisco-based company that sells its electronic health record (EHR) and other technology solutions to primary care providers — on Thursday announced its  acquisition of medical billing firm Lightning MD.
The deal will help Elation become an all-in-one technology platform for primary care offices, CEO Kyna Fong said in a recent interview. Fong founded Elation with her brother in 2010. The siblings grew up in Canada, where their father was a primary care physician — and a passionate one. He was so passionate that he ended up moving his family to the U.S. because he couldn’t “practice the…

Continue Reading
How to Leverage Diagnostic Development to Guard Against RSV, Flu and Covid-19 [Sponsored]

How to Leverage Diagnostic Development to Guard Against RSV, Flu and Covid-19 [Sponsored]

MedCity News

For the first two years of the Covid-19 pandemic, healthcare professionals focused on understanding the Covid-19 virus, how best to guard against it, and developing tests to detect it. They also tracked, aggregated, and analyzed health data to assess and monitor the public health threat on a regional, state and country-wide level. In the longer term, vaccine development and distribution were used to slow the spread to avoid a collapse of the health system and to reduce the potency of the virus for the majority of people.
More recently, attention has shifted to the long perceived threat of viruses coming together with…

Continue Reading
Blood Biotech Grifols Cuts Deep in the U.S. to Find €400M in Savings

Blood Biotech Grifols Cuts Deep in the U.S. to Find €400M in Savings

MedCity News

Grifols, a company that turns blood plasma into therapies for immunological disorders and other conditions, is laying off about 2,000 U.S. workers as part of a corporate restructuring projected to yield up to €400 million in annual cost savings, the biotech announced Wednesday.
The layoffs represent about 8% of the Barcelona-based company’s global workforce, but they will happen mainly in its U.S. plasma operations. That’s notable because as a company that relies on plasma, the U.S. is vital to its business. The starting point for Grifols’s therapies is blood plasma. Key to its drug-making process is fractionation, in which the protein components…

Continue Reading
BCBS Tennessee Unveils Health Disparities in First Health Equity Report

BCBS Tennessee Unveils Health Disparities in First Health Equity Report

MedCity News

BlueCross BlueShield of Tennessee unveiled its first Health Equity Report Tuesday, which analyzed six topics of health disparities: behavioral health, cancer, child and adolescent care, chronic condition management, Covid-19 and maternal health.
The report serves as a way to understand the inequities that exist among its members to determine ways the payer can address the disparities, said Dr. Andrea Willis, chief medical officer of BCBS Tennessee. “We wanted to get a better picture of the health issues and barriers to care faced by our members and Tennesseans as a whole, so that we could more effectively partner with health care providers to…

Continue Reading
HHS Aims To Reduce Prescription Drug Costs Through 3 New Models

HHS Aims To Reduce Prescription Drug Costs Through 3 New Models

MedCity News

The U.S. Department of Health & Human Services (HHS) unveiled three new models Tuesday that will be tested by the CMS Innovation Center and aim to lower prescription drug costs. The models include access to $2 generic drugs.
The news is in response to President Joe Biden’s executive order issued in October, which directed HHS to find ways to lower prescription drug costs and improve access to drug therapies for those enrolled in Medicare and Medicaid health plans. The models are meant to build on the Inflation Reduction Act of 2022, which includes allowing Medicare to negotiate lower prescription drug prices for…

Continue Reading
Heartpoint Global Hopes To Disrupt Congenital Pulmonary Hypertension Treatment With Minimally Invasive Device

Heartpoint Global Hopes To Disrupt Congenital Pulmonary Hypertension Treatment With Minimally Invasive Device

MedCity News

To correct high blood pressure of the pulmonary artery, which can arise from congenital defects of the heart, an artificial heart ucan cost upwards of $190,000. Heart disease accounted for about one in five deaths in 2020 in theUnited States.
Even minimally invasive pulmonary artery banding — a surgical technique that has been in use since Harry Truman was president — requires access to the chest cavity. A new treatment under development by HeartPoint Global seeks to provide a minimally invasive alternative to current treatments for pulmonary arterial hypertension associated with Congenital Heart Disease.A device delivered through the leg would cost only…

Continue Reading
MD Anderson’s Tech Puts Replay on Fast Path to Clinic With TCR NK Cell Therapies

MD Anderson’s Tech Puts Replay on Fast Path to Clinic With TCR NK Cell Therapies

MedCity News

A slew of biotech companies are pursuing research that could overcome limitations of current cell therapies. Startup creator Replay has a new subsidiary pushing toward the front of the pack with a therapeutic candidate on track to start its first human test this summer—about one year after Replay emerged from stealth. It owes this rapid progress to a cell therapy pioneer’s technology that has already been de-risked by a big pharmaceutical company.
Replay calls itself a genome writing company. With operations split between San Diego and London, the private equity-backed business launched last July with $55 million and a suite of technologies…

Continue Reading